1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–1259. DOI: 10.1016/s0140-6736(17)32154-2.
Google Scholar | Crossref | Medline2. GBD 2016 Headache Collaborators . Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954–976. DOI: 10.1016/s1474-4422(18)30322-3.
Google Scholar | Crossref | Medline3. May, A, Burstein, R. Hypothalamic regulation of headache and migraine. Cephalalgia 2019; 39: 1710–1719. DOI: 10.1177/0333102419867280.
Google Scholar | SAGE Journals | ISI4. Goadsby, PJ, Holland, PR, Martins-Oliveira, M, Hoffmann, J, Schankin, C, Akerman, S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 2017; 97: 553–622. DOI: 10.1152/physrev.00034.2015.
Google Scholar | Crossref | Medline | ISI5. Moskowitz, MA, Reinhard, JF, Romero, J, Melamed, E, Pettibone, DJ. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet 1979; 2: 883–885. DOI: 10.1016/s0140-6736(79)92692-8.
Google Scholar | Crossref | Medline | ISI6. Edvinsson, J, Viganò, A, Alekseeva, A, Alieva, E, Arruda, R, De Luca, C, D’Ettore, N, Frattale, I, Kurnukhina, M, Macerola, N. The fifth cranial nerve in headaches. J Headache Pain 2020; 21: 1–17. DOI: 10.1186/s10194-020-01134-1.
Google Scholar | Crossref | Medline7. Edvinsson, L, McCulloch, J, Uddman, R. Substance P: immunohistochemical localization and effect upon cat pial arteries in vitro and in situ. J Physiol 1981; 318: 251–258. DOI: 10.1113/jphysiol.1981.sp013862.
Google Scholar | Crossref | Medline | ISI8. Edvinsson, L, Uddman, R. Adrenergic, cholinergic and peptidergic nerve fibres in dura mater--involvement in headache? Cephalalgia 1981; 1: 175–179. DOI: 10.1046/j.1468-2982.1981.0104175.x.
Google Scholar | SAGE Journals | ISI9. Salter, MW, Henry, JL. Responses of functionally identified neurones in the dorsal horn of the cat spinal cord to substance P, neurokinin A and physalaemin. Neuroscience 1991; 43: 601–610. DOI: 10.1016/0306-4522(91)90319-j.
Google Scholar | Crossref | Medline10. Buzzi, MG, Moskowitz, MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202–206. DOI: 10.1111/j.1476-5381.1990.tb14679.x.
Google Scholar | Crossref | Medline | ISI11. Pietrobon, D, Moskowitz, MA. Pathophysiology of migraine. Annu Rev Physiol 2013; 75: 365–391. DOI: 10.1146/annurev-physiol-030212-183717.
Google Scholar | Crossref | Medline | ISI12. Edvinsson, L . Functional-role of perivascular peptides in the control of cerebral-circulation. Trends Neurosci 1985; 8: 126–131. DOI: 10.1016/0166-2236(85)90050-5.
Google Scholar | Crossref | ISI13. Edvinsson, L, Fredholm, BB, Hamel, E, Jansen, I, Verrecchia, C. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett 1985; 58: 213–217. DOI: 10.1016/0304-3940(85)90166-1.
Google Scholar | Crossref | Medline | ISI14. Goadsby, PJ, Edvinsson, L, Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–187. DOI: 10.1002/ana.410280213.
Google Scholar | Crossref | Medline | ISI15. Uddman, R, Edvinsson, L, Ekman, R, Kingman, T, McCulloch, J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985; 62: 131–136. DOI: 10.1016/0304-3940(85)90296-4.
Google Scholar | Crossref | Medline | ISI16. Levy, D, Burstein, R, Strassman, AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005; 58: 698–705. DOI: 10.1002/ana.20619.
Google Scholar | Crossref | Medline | ISI17. Edvinsson, L, Haanes, KA, Warfvinge, K, Krause, DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 2018; 14: 338–350. DOI: 10.1038/s41582-018-0003-1.
Google Scholar | Crossref | Medline18. Erbersberger, A, Averbeck, B, Messlinger, K, Reeh, PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999; 89: 901–907. DOI: 10.1016/S0306-4522(98)00366-2.
Google Scholar | Crossref | Medline19. Charles, A, Pozo-Rosich, P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019; 394: 1765–1774. DOI: 10.1016/S0140-6736(19)32504-8.
Google Scholar | Crossref | Medline20. Diener, HC, Group, RPRS. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 2003; 23: 183–185. DOI: 10.1046/j.1468-2982.2003.00496.x.
Google Scholar | SAGE Journals | ISI21. Goldstein, DJ, Offen, WW, Klein, EG, Phebus, LA, Hipskind, P, Johnson, KW, Ryan, RE. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 2001; 21: 102–106. DOI: 10.1046/j.1468-2982.2001.00161.x.
Google Scholar | SAGE Journals | ISI22. Goldstein, DJ, Wang, O, Saper, JR, Stoltz, R, Silberstein, SD, Mathew, NT. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997; 17: 785–790. DOI: 10.1046/j.1468-2982.1997.1707785.x.
Google Scholar | SAGE Journals | ISI23. Pennefather, JN, Lecci, A, Candenas, ML, Patak, E, Pinto, FM, Maggi, CA. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004; 74: 1445–1463. DOI: 10.1016/j.lfs.2003.09.039.
Google Scholar | Crossref | Medline | ISI24. Ständer, S, Siepmann, D, Herrgott, I, Sunderkötter, C, Luger, TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5: e10968. DOI: 10.1371/journal.pone.0010968.
Google Scholar | Crossref | Medline25. Yosipovitch, G, Ständer, S, Kerby, MB, Larrick, JW, Perlman, AJ, Schnipper, EF, Zhang, X, Tang, JY, Luger, T, Steinhoff, M. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol 2018; 78: 882–891.e10. DOI: 10.1016/j.jaad.2018.02.030.
Google Scholar | Crossref | Medline26. Ständer, S, Yosipovitch, G. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus. Br J Dermatol 2019; 181: 932–938. DOI: 10.1111/bjd.18025.
Google Scholar | Crossref | Medline27. Edvinsson, JCA, Warfvinge, K, Krause, DN, Blixt, FW, Sheykhzade, M, Edvinsson, L, Haanes, KA. C-fibers may modulate adjacent Adelta-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J Headache Pain 2019; 20 105. 2019/11/14. DOI: 10.1186/s10194-019-1055-3.
Google Scholar | Crossref28. Eftekhari, S, Salvatore, CA, Calamari, A, Kane, SA, Tajti, J, Edvinsson, L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010; 169: 683–696. DOI: 10.1016/j.neuroscience.2010.05.016.
Google Scholar | Crossref | Medline | ISI29. Mantyh, PW . Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry 2002; 63: 6–10.
Google Scholar | Medline | ISI30. Lee, W, Moussaoui, S, Moskowitz, M. Oral or parenteral non-peptide NK1 receptor antagonist RPR 100893 blocks neurogenic plasma extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol 1994; 112: 920–924. DOI: 10.1111/j.1476-5381.1994.tb13168.x.
Google Scholar | Crossref | Medline | ISI31. Cutrer, F, Moussaoui, S, Garret, C, Moskowitz, M. The non-peptide neurokinin-1 antagonist, RPR 100893, decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation. Neuroscience 1995; 64: 741–750. DOI: 10.1016/0306-4522(94)00428-8.
Google Scholar | Crossref | Medline | ISI32. Diener, H . RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 2003; 23: 183–185. DOI: 10.1046/j.1468-2982.2003.00496.x.
Google Scholar | SAGE Journals | ISI33. Goldstein, D, Wang, O, Saper, J, Stoltz, R, Silberstein, S, Mathew, N. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997; 17: 785–790. DOI: 10.1046/j.1468-2982.1997.1707785.x.
Google Scholar | SAGE Journals | ISI34. Harriott, AM, Strother, LC, Vila-Pueyo, M, Holland, PR. Animal models of migraine and experimental techniques used to examine trigeminal sensory processing. J Headache Pain 2019; 20: 91. DOI: 10.1186/s10194-019-1043-7.
Google Scholar | Crossref | Medline35. Edvinsson, L, Rosendal-Helgesen, S, Uddman, R. Substance P: localization, concentration and release in cerebral arteries, choroid plexus and dura mater. Cell Tissue Res 1983; 234: 1–7. DOI: 10.1007/BF00217397.
Google Scholar | Crossref | Medline | ISI36. Zieglgänsberger, W . Substance P and pain chronicity. Cell Tissue Res 2019; 375: 227–241. DOI: 10.1007/s00441-018-2922-y.
Google Scholar | Crossref | Medline37. Malcangio, M, Bowery, NG. Peptide autoreceptors: does an autoreceptor for substance P exist? Trends Pharmacol Sci 1999; 20: 405–407. DOI: 10.1016/S0165-6147(99)01388-7.
Google Scholar | Crossref | Medline38. Mashaghi, A, Marmalidou, A, Tehrani, M, Grace, PM, Pothoulakis, C, Dana, R. Neuropeptide substance P and the immune response. Cell Mol Life Sci 2016; 73: 4249–4264. DOI: 10.1007/s00018-016-2293-z.
Google Scholar | Crossref | Medline | ISI39. Nyberg, F, Le Greves, P, Sundqvist, C, Terenius, L. Characterization of substance P (1-7) and (1-8) generating enzyme in human cerebrospinal fluid. Biochem Biophys Res Commun 1984; 125: 244–250. DOI: 10.1016/S0006-291X(84)80360-5.
Google Scholar | Crossref | Medline40. Friberg, L, Olesen, J, Olsen, TS, Karle, A, Ekman, R, Fahrenkrug, J. Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura. Cephalalgia 1994; 14: 47–54. DOI: 10.1046/j.1468-2982.1994.1401047.x.
Google Scholar | SAGE Journals | ISI41. Sicuteri, F, Fanciullacci, M, Geppetti, P, Renzi, D, Caleri, D, Spillantini, MG. Substance P mechanism in cluster headache: evaluation in plasma and cerebrospinal fluid. Cephalalgia 1985; 5: 143–149. DOI: 10.1046/j.1468-2982.1985.0503143.x.
Google Scholar | SAGE Journals | ISI42. Sherman, DL, Tait, S, Melrose, S, Johnson, R, Zonta, B, Court, FA, Macklin, WB, Meek, S, Smith, AJ, Cottrell, DF. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron 2005; 48: 737–742